✦ LIBER ✦

Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease

✍ Scribed by Costa, F

Book ID: 124164660
Publisher: BMJ Publishing Group
Year: 2005
Tongue: English
Weight: 113 KB
Volume: 54
Category: Article
ISSN: 0017-5749
DOI: 10.1136/gut.2004.043406

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Does fecal calprotectin predict relapse

Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?

✍ Valle García-Sánchez; Eva Iglesias-Flores; Raúl González; Javier P. Gisbert; Jos 📂 Article 📅 2010 🏛 Oxford University Press 🌐 English ⚖ 367 KB

P163 FAECAL CALPROTECTIN IS A PREDICTIVE

P163 FAECAL CALPROTECTIN IS A PREDICTIVE MARKER OF CLINICAL RELAPSE IN CROHN'S DISEASE

✍ L. Kallel; N. Ben Mahmoud; M. Feki; I. Ayadi; S. Matri; S. Karoui; M. Fekih; J. 📂 Article 📅 2008 🏛 Oxford University Press ⚖ 63 KB

Prediction of Crohn’s disease relapse wi

Prediction of Crohn’s disease relapse with faecal calprotectin in infliximab responders: a prospective study

✍ D. Laharie; S. Mesli; F. El Hajbi; E. Chabrun; E. Chanteloup; M. Capdepont; S. R 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB

Prediction of Crohn’s disease relapse wi

Prediction of Crohn’s disease relapse with faecal calprotectin in infliximab responders: a prospective study

✍ A. R. Deshpande; S. Strobel 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB

Atypical pANCA as a marker of indetermin

Atypical pANCA as a marker of indeterminate colitis for the prediction of ulcerative colitis and crohn’s disease

✍ Assoc. Prof. Murat Kekilli MD, Yavuz Beyazit MD… 📂 Article 📅 2013 🏛 Springer Vienna 🌐 English ⚖ 638 KB

Prediction of treatment refractoriness i

Prediction of treatment refractoriness in ulcerative colitis and Crohn's disease—do we have reliable markers?

✍ Dr. Cornelia M. Gelbmann 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 962 KB

Treatment refractoriness is a severe problem in the management of patients with ulcerative colitis and Crohn's disease. Despite some promising new therapeutic approaches, corticosteroids are still the preferential primary treatment for moderate to severe Crohn's disease and of severe ulcerative coli